Press Release

Media Contact
Matthias Link
T +49 6172 609-2872
matthias.link@fresenius.com
Contact for analysts andinvestors
Dr. Dominik Heger
T +49 6172 609-2601
dominik.heger@fmc-ag.com
www.freseniusmedicalcare.com

October 8, 2018

Fresenius Medical Care supports access to hemodiafiltration for UK
dialysis patients
Fresenius Medical Care, the world’s largest provider of dialysis products and services,supports the recommendation by the United Kingdom’s National Institute for Health andCare Excellence (NICE) to facilitate population healthcare management for UK patientswith end-stage renal disease. In a guideline on renal replacement therapy published onOctober 3, 2018, NICE, a non-departmental public body of the UK’s Department ofHealth, advises health and social care professionals to consider hemodiafiltration (HDF)
rather than high-flux hemodialysis (HD) if the patient is treated in-center, due to thepositive impact on patient outcomes and cost-effectiveness.
High-flux HD is the application of high-flux dialyzers to remove a broad spectrum of smalland large uremic toxins in order to contribute towards better management of dialysispatients. HDF adds a convective component to the high-flux HD treatment, making iteven more effective in removing larger toxins and further improving patient outcomes.
In order to provide evidence-based guidance, NICE systematically reviewed best
available renal replacement therapy studies and conducted an economic evaluation. The
assessment identified clear benefits of HDF treatment for both renal disease patients andthe national healthcare system, as HDF is not only considered cost-effective but is also
expected to decrease mortality rates among patients.
Fresenius Medical Care has a long-standing commitment to make HDF available topatients to achieve the best possible outcomes. The company has developed innovativePage 1/2

technologies which automatically maximize substitution rates in HDF and support theapplication of HighVolumeHDF®. This makes HDF treatments as simple as HD, andallows HDF treatments to be delivered at the same cost as HD in the UK.
Dr. Katarzyna Mazur-Hofsaess, Chief Executive Officer of Fresenius Medical Care forEurope, the Middle East and Africa, said: “The NICE guidelines incorporate the existingevidence base for the benefits of HDF therapy. We are convinced that ourHighVolumeHDF® therapy platform provides the easiest way for the user to deliver HDF
to patients. Our commitment to make HighVolumeHDF® available to all patients acrossthe UK remains a top priority for us.”Fresenius Medical Care is the world's largest provider of products and services for individuals withrenal diseases of which around 3.2 million patients worldwide regularly undergo dialysis treatment.
Through its network of 3,815 dialysis clinics, Fresenius Medical Care provides dialysis treatmentsfor 325,188 patients around the globe. Fresenius Medical Care is also the leading provider ofdialysis products such as dialysis machines or dialyzers. Along with its core business, the company
provides related medical services in the field of Care Coordination. Fresenius Medical Care is listedon the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company’s website at www.freseniusmedicalcare.com.
Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actualresults could differ materially from those described in these forward-looking statements due to certain factors,including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate
fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These andother risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S.
Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any
responsibility to update the forward-looking statements in this release.

Page 2/2